World J Mens Health.
2013 Apr;31(1):31-35.
Treatment Strategy for Non-Responders to PDE5 Inhibitors
- Affiliations
-
- 1Department of Urology, Pusan National University School of Medicine, Busan, Korea. joon501@naver.com
- 2Medical Rresearch Iinstitute, Pusan National University Hospital, Busan, Korea.
Abstract
- Currently, phosphodiesterase type 5 (PDE5) inhibitors are the initial treatment option for erectile dysfunction. The reported efficacy of PDE5 inhibitors is about 70%, although it is significantly lower in difficult-to-treat subpopulations. Treatment failures might be due to the severity of the underlying pathophysiology, improper use of medication, unrealistic patient expectations, difficult relationship dynamics, severe performance anxiety, and other psychological problems. Physicians must address these issues to identify true treatment failures attributable to the drugs. This article discusses factors that might affect the response to PDE5 inhibitors and develops a strategy to maximize the overall efficacy of PDE5 inhibitors in initial non-responders to PDE5 inhibitors.
Keyword
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
- New PDEs Inhibitors for Erectile Dysfunction
- Pharmacokinetics, Efficacy, and Safety of Selective Inhibitors of Phosphodiesterase Type 5 and Sublingual Apomorphine for the Treatment of Erectile Dysfunction
- The Analysis of Clinical Efficacy of Phosphodiesterase 5 Inhibitors for Erectile Dysfunction using SS-Penogram
- Changes in Clinical Applications of Oral Drugs for Erectile Dysfunction
